
REFERENCES

1. CDC. HIV testing among pregnant women – United States and Canada, 1998–2001. MMWR. 2002;51:1013–1016. Available at: <http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5145a1.htm>.
2. Dorenbaum A, Cunningham CK, Gelber RD, et al. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial. *Journal of the American Medical Association*. 2002;288:189–198.
3. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. *The Lancet*. 1999;354:795–802.
4. Wade NA, Birkhead GS, Warren BL, et al. Abbreviated regimen of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. *New England Journal of Medicine*. 1998;339:1409–1414.
5. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. *New England Journal of Medicine*. 1994; 331:1173–1180.
6. Stringer EM, Stringer JS, Cliver SP, Goldenberg RL, Goepfert AR. Evaluation of a new testing policy for human immunodeficiency virus to improve screening rates. *Obstetrics & Gynecology*. 2001;98:1104–1108.